We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Study Explains Genetic Roots of Alzheimer's

By Biotechdaily staff writers
Posted on 25 Apr 2007
A study has uncovered a molecular mechanism that links the susceptibility gene to the process of Alzheimer's disease onset.

Scientists have known for more than a decade that individuals with a certain gene are at higher risk for developing Alzheimer's disease. More...
Now, a new study helps explain why this is so. The findings appear in the April 11, 2007, issue of The Journal of Neuroscience and may lead to new pathways for development of Alzheimer's therapeutics.

The research, led by scientists at the Oklahoma Medical Research Foundation (OMRF; www.omrf.org), has uncovered a molecular mechanism that links the susceptibility gene to the process of Alzheimer's disease onset. Approximately 15% of the population carries a gene that causes their bodies to produce a lipoprotein--a combination of fat and protein that transports lipids in the blood--known as apolipoprotein (Apo) E4. Studies have found that those who inherit the E4 gene from one parent are three times more likely than average to develop Alzheimer's, while those who get the gene from both parents have a tenfold risk of developing the disease.

In the new study, OMRF's Jordan J.N. Tang, Ph.D., and his colleagues discovered that ApoE4 attaches itself to a particular receptor on the surface of brain cells. That receptor, in turn, adheres to a protein known as amyloid precursor protein. The brain cells then transport the entire protein mass inside.

Once inside, cutting enzymes--called proteases--attack the amyloid precursor protein. These cuts create protein fragments that, when present in the brain for long periods of time, are believed to cause the cell death, memory loss, and neurologic dysfunction characteristic of Alzheimer's. Although researchers have known for more than a decade that ApoE4 was involved--somehow--in development of Alzheimer's, Dr. Tang's new study is the first to connect the process of protein fragment formation to ApoE4.

While roughly one in seven persons carry the E4 gene, the remainder of the population carries only two variations, E2 and E3, of that gene. These individuals have a markedly lower incidence of Alzheimer's than those who carry the E4 gene. The new study found that ApoE4 produced more protein fragments than did E2 or E3.

"ApoE4 apparently interacts better with the receptor than its cousins,” said Dr. Tang. "This may explain why people who carry the E4 gene have a higher risk of developing Alzheimer's. These findings may allow us to investigate the possibility of therapeutic intervention at different points in the process.” For example, he said, such efforts might focus on developing a compound to interfere with the receptor's ability to adhere to ApoE4. "There currently is no effective treatment for Alzheimer's disease, so we must explore every possible option to find a way to stop it,” he continued.

"Dr. Tang's study shows a beautiful biochemical connection between a genetic risk factor and the development of a disease,” said OMRF president Stephen Prescott, M.D. "This work opens the door to the development of alternate methods for treating--and perhaps even preventing--Alzheimer's.”


Related Links:
OMRF

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.